Lexaria Bioscience Corp. (LEXX) stock
LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
$4.28+0.10 (+2.39%)
Close on Nov 18, 2026Market cap $106.09MP/E –Yield –
Lexaria Bioscience operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Lexaria Bioscience's operating income for the twelve months ending May 31, 2026 was -$7.71M. For fiscal 2025 it was -$11.88M. The highest annual figure on record is -$1.28M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | -$11.88M | – |
| FY2024 | Aug 31, 2024 | -$5.75M | – |
| FY2023 | Aug 31, 2023 | -$6.53M | – |
| FY2022 | Aug 31, 2022 | -$6.62M | – |
| FY2021 | Aug 31, 2021 | -$5.69M | – |
| FY2016 | Aug 31, 2016 | -$1.28M | – |
| FY2015 | Aug 31, 2015 | -$1.98M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | May 31, 2026 | -$1.99M | – |
| Q2 FY2026CQ1 2026 | Feb 28, 2026 | -$1.45M | – |
| Q1 FY2026CQ4 2025 | Nov 30, 2025 | -$1.57M | – |
| Q4 FY2025CQ3 2025 | Aug 31, 2025 | -$2.69M | – |
| Q3 FY2025CQ2 2025 | May 31, 2025 | -$3.75M | – |
| Q2 FY2025CQ1 2025 | Feb 28, 2025 | -$2.75M | – |
| Q1 FY2025CQ4 2024 | Nov 30, 2024 | -$2.69M | – |
| Q4 FY2024CQ3 2024 | Aug 31, 2024 | -$2.20M | – |
| Q3 FY2024CQ2 2024 | May 31, 2024 | -$1.74M | – |
| Q2 FY2024CQ1 2024 | Feb 29, 2024 | -$668.01K | – |
| Q1 FY2024CQ4 2023 | Nov 30, 2023 | -$1.14M | – |
| Q4 FY2023CQ3 2023 | Aug 31, 2023 | -$1.11M | – |
| Q3 FY2023CQ2 2023 | May 31, 2023 | -$2.40M | – |
| Q2 FY2023CQ1 2023 | Feb 28, 2023 | -$1.32M | – |
| Q1 FY2023CQ4 2022 | Nov 30, 2022 | -$1.70M | – |
| Q4 FY2022CQ3 2022 | Aug 31, 2022 | -$748.55K | – |
| Q3 FY2022CQ2 2022 | May 31, 2022 | -$2.42M | – |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -$1.30M | – |
| Q3 FY2021CQ2 2021 | May 31, 2021 | -$2.57M | – |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | -$1.38M | – |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | -$578.71K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | -$464.98K | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | -$400.55K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | -$326.75K | – |
See a number that looks wrong?